CIK 0001314052 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · fiscal year ends 09/30
| FY2023 | FY2022 | FY2020 | FY2016 | |
|---|---|---|---|---|
| Net income (USD) | -48.0 M | -26.3 M | -26.3 M | |
| Diluted EPS (USD/shares) | -0.62 | -0.42 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-20 | 8-K | FORM 8-K items 8.01,9.01 | 2026-10-20 |
| 2026-10-15 | 8-K | FORM 8-K items 8.01,9.01 | 2026-10-15 |
| 2026-10-05 | 3 | 3 | 2026-09-24 |
| 2026-10-05 | 3 | 3 | 2026-09-24 |
| 2026-09-28 | 4 | 4 | 2026-09-24 |
| 2026-09-28 | 8-K | FORM 8-K items 5.01,5.07 | 2026-09-24 |
| 2026-09-21 | DFAN14A | DFAN14A | |
| 2026-09-18 | DFAN14A | DFAN14A | |
| 2026-09-17 | DFAN14A | DFAN14A | |
| 2026-09-15 | DEFA14A | FORM DEFA14A | |
| 2026-09-15 | DFAN14A | DFAN14A | |
| 2026-09-14 | DEFA14A | FORM DEFA14A | |
| 2026-09-10 | DFAN14A | DFAN14A | |
| 2026-09-10 | DFAN14A | DFAN14A | |
| 2026-09-09 | DFAN14A | DFAN14A | |
| 2026-09-09 | 8-K | FORM 8-K items 8.01 | 2026-09-09 |
| 2026-09-08 | DEFA14A | FORM DEFA14A | |
| 2026-09-04 | DEFA14A | FORM DEFA14A | |
| 2026-09-04 | DFAN14A | DFAN14A | |
| 2026-09-03 | DFAN14A | DFAN14A | |
| 2026-09-02 | 8-K | FORM 8-K items 8.01,9.01 | 2026-09-02 |
| 2026-09-02 | DFAN14A | DFAN14A | |
| 2026-09-01 | DEFA14A | FORM DEFA14A | |
| 2026-08-31 | DEFA14A | FORM DEFA14A | |
| 2026-08-28 | 10-Q | FORM 10-Q | 2026-06-30 |
Forms on file (last 1,000): 4 168, 8-K 131, 10-Q 55, 3 27, UPLOAD 22, 10-K 18, DEFA14A 16, DEF 14A 16. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=AVXL (0.002 USD), /gw/filings/filings?ticker=AVXL&form=8-K, /gw/filings/facts?ticker=AVXL&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange